144 related articles for article (PubMed ID: 23444403)
1. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma.
Ouyang J; Plütschow A; Pogge von Strandmann E; Reiners KS; Ponader S; Rabinovich GA; Neuberg D; Engert A; Shipp MA
Blood; 2013 Apr; 121(17):3431-3. PubMed ID: 23444403
[TBL] [Abstract][Full Text] [Related]
2. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
[TBL] [Abstract][Full Text] [Related]
3. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma.
Juszczynski P; Ouyang J; Monti S; Rodig SJ; Takeyama K; Abramson J; Chen W; Kutok JL; Rabinovich GA; Shipp MA
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13134-9. PubMed ID: 17670934
[TBL] [Abstract][Full Text] [Related]
4. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
Karube K; Niino D; Kimura Y; Ohshima K
Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
[TBL] [Abstract][Full Text] [Related]
5. Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma.
Kowalska M; Tajer J; Chechlinska M; Fuksiewicz M; Kotowicz B; Kaminska J; Walewski J
Med Oncol; 2012 Sep; 29(3):2143-7. PubMed ID: 21717212
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.
Plattel WJ; Alsada ZN; van Imhoff GW; Diepstra A; van den Berg A; Visser L
Br J Haematol; 2016 Dec; 175(5):868-875. PubMed ID: 27610595
[TBL] [Abstract][Full Text] [Related]
7. Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma.
Chen K; Cai Y; Zhang M; Wu Z; Wu Y
Pediatr Blood Cancer; 2018 Sep; 65(9):e27229. PubMed ID: 29797641
[TBL] [Abstract][Full Text] [Related]
8. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
[TBL] [Abstract][Full Text] [Related]
9. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
10. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22.
Niens M; Visser L; Nolte IM; van der Steege G; Diepstra A; Cordano P; Jarrett RF; Te Meerman GJ; Poppema S; van den Berg A
Br J Haematol; 2008 Mar; 140(5):527-36. PubMed ID: 18275430
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
12. Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.
Femel J; van Hooren L; Herre M; Cedervall J; Saupe F; Huijbers EJM; Verboogen DRJ; Reichel M; Thijssen VL; Griffioen AW; Hellman L; Dimberg A; Olsson AK
Cancer Immunol Immunother; 2022 Aug; 71(8):2029-2040. PubMed ID: 35018481
[TBL] [Abstract][Full Text] [Related]
13. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.
Aldinucci D; Celegato M; Casagrande N
Cancer Lett; 2016 Sep; 380(1):243-52. PubMed ID: 26474544
[TBL] [Abstract][Full Text] [Related]
14. Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.
Verschuere T; Van Woensel M; Fieuws S; Lefranc F; Mathieu V; Kiss R; Van Gool SW; De Vleeschouwer S
J Neurooncol; 2013 Oct; 115(1):9-17. PubMed ID: 23824536
[TBL] [Abstract][Full Text] [Related]
15. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.
Tecchio C; Nadali G; Scapini P; Bonetto C; Visco C; Tamassia N; Vassilakopoulos TP; Pangalis GA; Calzetti F; Nardelli B; Roschke V; Gottardi M; Zampieri F; Gherlinzoni F; Facchetti F; Pizzolo G; Cassatella MA
Br J Haematol; 2007 Jun; 137(6):553-9. PubMed ID: 17539776
[TBL] [Abstract][Full Text] [Related]
16. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission.
Rueda A; Olmos D; Villareal V; Torres E; Pajares BI; Alba E
Clin Lymphoma Myeloma; 2007 May; 7(6):400-5. PubMed ID: 17621405
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD47 antigen in Reed-Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma.
López-Pereira B; Fernández-Velasco AA; Fernández-Vega I; Corte-Torres D; Quirós C; Villegas JA; Palomo P; González S; González AP; Payer Á; Bernal T; Moro-García MA; Alonso-Arias R; Alonso-Álvarez S; Colado E
Clin Transl Oncol; 2020 May; 22(5):782-785. PubMed ID: 31359339
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling.
Lawrie CH; Marafioti T; Hatton CS; Dirnhofer S; Roncador G; Went P; Tzankov A; Pileri SA; Pulford K; Banham AH
Int J Cancer; 2006 Jun; 118(12):3161-6. PubMed ID: 16395706
[TBL] [Abstract][Full Text] [Related]
19. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment.
Hsi ED
Leuk Lymphoma; 2008 Sep; 49(9):1668-80. PubMed ID: 18798102
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.
Sarris AH; Kliche KO; Pethambaram P; Preti A; Tucker S; Jackow C; Messina O; Pugh W; Hagemeister FB; McLaughlin P; Rodriguez MA; Romaguera J; Fritsche H; Witzig T; Duvic M; Andreeff M; Cabanillas F
Ann Oncol; 1999 Apr; 10(4):433-40. PubMed ID: 10370786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
